OVID Provides Update on OV101 Program and the Prioritization of its Resources
April 19, 2021 08:00 ET
|
Ovid Therapeutics Inc.
Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID’s Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly...
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
March 30, 2021 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with...
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
March 15, 2021 08:00 ET
|
Ovid Therapeutics Inc.
Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million...
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
December 16, 2020 07:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
December 01, 2020 16:52 ET
|
Ovid Therapeutics Inc.
OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDAPivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome...
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
November 23, 2020 16:01 ET
|
Ovid Therapeutics Inc.
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020 16:10 ET
|
Ovid Therapeutics Inc.
On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational...
Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program
October 14, 2020 07:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress
October 12, 2020 07:00 ET
|
Ovid Therapeutics Inc.
Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics...
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies
September 30, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency...